Testicular cancer · 13 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Chlorambucil, Dactinomycin, Methotrexate Variant #01 | — | R 44 125 | 25d | — | — | ~1 | ~R 44 125 indirect | — |
M-TIP Variant #01 | — | R 16 753 | — | — | — | ~4 | ~R 67 011 indirect | — |
VIP Variant #01 | — | R 13 835 | 21d | — | — | ~4 | ~R 55 342 indirect | — |
VAB-6 Variant #01 Partial | — | R 11 816 | 28d | — | — | ~2 | ~R 23 633 indirect | — |
CISCA/VB Variant #01 Partial | — | R 9 221 | 21d | — | — | ~3 | ~R 27 663 indirect | — |
PVeBV Variant #01 Partial | — | R 4 967 | 21d | — | — | ~4 | ~R 19 866 indirect | — |
Bleomycin and Vinblastine Variant #01 Partial | — | R 2 888 | 35d | — | — | ~6 | ~R 17 330 indirect | — |
Accelerated BEP Variant #01 Partial | — | R 2 787 | 14d | — | — | ~4 | ~R 8 361 indirect | — |
BEP Variant #01 Partial | — | R 2 787 | 21d | — | — | ~3 | ~R 8 361 indirect | — |
BVP Variant #01 Partial | — | R 2 180 | 28d | — | — | ~4 | ~R 8 718 indirect | — |
C-BOP Variant #01 Partial | — | R 2 012 | 14d | — | — | ~2 | ~R 4 023 indirect | — |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | ~5.0 mo | ~10.2 mo | ~4 | ~R 7 277 PFS proxy · indirect | 13 |
Bleomycin and Vincristine (BO) Variant #01 Partial | — | R 327 | 14d | — | — | ~1 | ~R 327 indirect | — |
13 of 13 regimens shown